Mid-stage data give Guillain-Barré patients cause for optimism

Sweden-based biotech Hansa Biopharma (Nasdaq: HNSA) has released promising full results from a Phase II study evaluating imlifidase, its IgG-cleaving enzyme, in severe Guillain-Barré syndrome (GBS).

The study demonstrated that patients treated with imlifidase and intravenous immunoglobulin achieved faster recovery milestones compared to a real-world comparator group.

Patients achieved significant functional improvements, including expedited recovery of muscle strength and a quicker return to independent walking.